Biogen reports 52-week phase 2 Litifilimab data
Biogen said Litifilimab showed rapid and durable efficacy in new 52-week phase 2 data from the ongoing AMETHYST study in cutaneous lupus erythematosus.
Biogen said Litifilimab showed rapid and durable efficacy in new 52-week phase 2 data from the ongoing AMETHYST study in cutaneous lupus erythematosus.